In situ epigenome engineering approach for genomically scarless, durable, and non-addictive management of pain.
INTRODUCTION
Chronic pain affects between 19% to 50% of the world population [1] [2] [3] [4] , with more than 100 million people affected in the U.S. alone 5 . Moreover, the number of people reporting chronic pain is expected to increase by 2035 due to the aging global population and prevalence of chronic diseases 6, 7 . While chronic pain is more prevalent than cancer, diabetes and cardiovascular disease combined 8 , drug development has not undergone the remarkable progress seen in these other therapeutic areas. Furthermore, current standard of care for chronic pain often relies on opioids, which can have adverse side effects and significant addiction risk. Despite decades of research, the goal of achieving broadly effective, long-lasting, non-addictive therapeutics for chronic pain has remained elusive.
Pain arising from somatic or nerve injury/pathologies typically arises by activation of populations of primary afferent neurons which are characterized by activation thresholds associated with tissue injury and by sensitivity to products released by local tissue injury and inflammation. These afferents terminate in the spinal dorsal horn, where this input is encoded and transmitted by long ascending tracts to the brain, where it is processed into the pain experience. The cell body of a primary afferent lies in its dorsal root ganglion (DRG). These neuronal cell bodies, synthesize the voltage gated sodium channels that serve to initiate and propagate the action potential [9] [10] [11] . While local anesthetics can yield a dense anesthesia, previous work has in fact shown that nonspecific sodium channel blockers such as lidocaine delivered systemically at subanesthetic concentrations were able to have selective effects upon hyperpathia in animal models and humans [12] [13] [14] [15] .
It is now known that there are nine voltage-gated sodium channel subtypes along with numerous splice variants. Of note, three of these isotypes: Na V 1.7 16, 17 , Na V 1.8 [18] [19] [20] , and Na V 1.9 21, 22 have been found to be principally expressed in primary afferent nociceptors. The relevance of these isotypes to human pain has been suggested by the observation that a loss-of-function mutation in Na V 1.7 (SCN9A) leads to congenital insensitivity to pain (CIP), a rare genetic disorder. Conversely, gain of function mutations yield anomalous hyperpathic states [23] [24] [25] [26] [27] [28] [29] . Based on these observations, the Na V 1.7 channel has been considered an attractive target for addressing pathologic pain states 3 and for developing chronic pain therapies 17, [29] [30] [31] . Efforts to develop selective small molecule inhibitors have, however, been hampered due to the sequence similarity between Na V subtypes. Many small-molecule drugs targeting Na V 1.7 have accordingly failed due to side effects caused by lack of targeting specificity or their bioavailability by the systemic route 32 . Additionally, antibodies have faced a similar situation, since there is a tradeoff between selectivity and potency due to the binding of a specific (open or close) conformation of the channel, with binding not always translating into successful channel inhibition [33] [34] [35] [36] . Further, it is not clear that such antibodies can gain access to the appropriate Na V 1.7 channels and yield a reliable block of their function. Consequently, in spite of preclinical studies demonstrating that decreased Na V 1.7 activity leads to a reduction in inflammatory and neuropathic pain [16] [17] [18] [19] [20] [21] [22] 37 , no molecule targeting this gene product has reached the final phase of clinical trials 32 . We therefore took an alternative approach by epigenetically modulating the expression of Na V 1.7 using two genome engineering tools, clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 (CRISPR-Cas9) and zinc-finger proteins (ZFP), such that one could engineer highly specific, long-lasting and reversible treatments for pain.
Through its ability to precisely target disease-causing DNA mutations, the CRISPR-Cas9 system has emerged as a potent tool for genome manipulation, and has shown therapeutic efficacy in multiple animal models of human diseases [38] [39] [40] [41] [42] [43] [44] . However, permanent genome editing, leading to permanent alteration of pain perception, may not be desirable. For example, pain can be a discomforting sensory and emotional experience, but it plays a critical role alerting of tissue damage. Permanent ablation could thus have detrimental consequences. For these reasons, we have employed a catalytically inactivated "dead" Cas9 (dCas9, also known as CRISPRi), which does not cleave DNA but maintains its ability to bind to the genome via a guide-RNA (gRNA), and fused it to a repressor domain (Krüppel-associated box, KRAB) to enable nonpermanent gene repression of Na V 1.7. Previously, we and others have shown that through addition of a KRAB epigenetic repressor motif to dCas9, gene repression can be enhanced with a high level of specificity both in vitro [45] [46] [47] [48] [49] and in vivo 50, 51 . This transcriptional modulation system takes advantage of the high specificity of CRISPR-Cas9 while simultaneously increasing the safety profile, as no permanent modification of the genome is performed. As a second approach for in situ epigenome repression of Na V 1.7, we also utilized zinc-finger-KRAB proteins (ZFP-KRAB), consisting of a DNAbinding domain made up of Cys 2 His 2 zinc fingers fused to a KRAB repressor. ZFP 4 constitute the largest individual family of transcriptional modulators encoded by the genomes of higher organisms 52 , and with prevalent synthetic versions engineered on human protein chasses present a potentially low immunogenicity in vivo targeting approach [53] [54] [55] . We sought to produce a specific anatomic targeting of the gene regulation by delivering both epigenetic tools in an adeno-associated virus (AAV) construct into the spinal intrathecal space. Of note, many AAVs have been shown to produce a robust transduction of the dorsal root ganglion [56] [57] [58] . This approach has several advantages as it permits the use of minimal viral loads and reduces the possibility of systemic immunogenicity.
Since pain perception is etiologically diverse and multifactorial, several rodent pain models have been utilized to study pain signaling and pain behaviors 59 . In the present work we sought to characterize the effects of CRISPR-mediated knock down of Na V 1.7 using three mechanistically distinct models: i) thermal sensitivity in control (normal) and unilateral inflammation-sensitized hind paw; ii) a poly neuropathy induced by a chemotherapeutic yielding a bilateral hind paw tactile allodynia and, iii) a spinally evoked bilateral hind paw tactile allodynia induced by spinal activation of purine receptors. Pain due to tissue injury and inflammation results from a release of factors that sensitize the peripheral terminal of the nociceptive afferent neuron. This phenotype can be studied through local application of carrageenan to the paw resulting in inflammation, swelling, increased expression of Na V 1.7 60 and a robust increase in thermal and mechanical sensitivity (hyperalgesia) 61, 62 . Chemotherapy to treat cancer often leads to a polyneuropathy characterized by increased sensitivity to light touch (e.g. tactile allodynia) and cold. Paclitaxel is a commonly used chemotherapeutic that increases the expression of Na V 1.7 in the nociceptive afferents 63, 64 and induces a robust allodynia in the animal models [65] [66] [67] . Finally, ATP (adenosine triphosphate) by an action on a variety of purine receptors expressed on afferent terminals and second order neurons and non neuronal cells has been broadly implicated in inflammatory, visceral and neuropathic pain states [57] [58] [59] [60] . Thus, intrathecal delivery of a stable ATP analogue (BzATP: 2',3'-O-(4-benzoylbenzoyl)-ATP) results in a long-lasting allodynia in mice 71, 72 .
Thus, we first tested various KRAB-dCas9 and ZFP-KRAB constructs in a mouse neuroblastoma cell line that expresses Na V 1.7 (Neuro2a) and optimized repression levels. We next packaged the constructs with the strongest in vitro repression into AAV9 and injected these intrathecally into adult C57BL/6J mice. After 21 days, we induced paw inflammation via injection of carrageenan, and tested for thermal hyperalgesia. Our 5 results demonstrated in vivo repression of Na V 1.7 and a decrease in thermal hyperalgesia. Similarly, we tested our epigenome strategy in two neuropathic pain models: chemotherapy-induced (paclitaxel) and BzATP-induced neuropathic pain. The results in the paclitaxel-induced neuropathic pain model indicate that repression of Na V 1.7 leads to reduced tactile and cold allodynia. In addition, KRAB-dCas9 injected mice showed reduced tactile allodynia after administration of the ATP analogue BzATP.
As many pain states occurring after chronic inflammation and nerve injury represent an enduring condition, typically requiring constant re-medication, these genetic approaches provide ongoing and controllable regulation of this aberrant processing. Overall, these in situ epigenetic approaches could represent a viable replacement for opioids and serve as a potential therapeutic approach for long lasting chronic pain.
RESULTS

In vitro optimization of epigenetic engineering tools to enable Na V 1.7 repression.
With the goal of developing a therapeutic product that relieves chronic pain in a non-permanent, non-addictive and long-lasting manner, we explored the use of two independent genetic approaches to inhibit the transmission of pain at the spinal level ( Figure 1a ). To establish robust Na V 1.7 repression, we first compared in vitro repression efficacy of Na V 1.7 using KRAB-dCas9 and ZFP-KRAB constructs. Towards this, we cloned ten guide-RNAs (gRNAs; Supplementary Table 1 ) -designed by an in silico tool 73 that predicts highly effective gRNAs based on chromatin position and sequence features-into our previously developed split-dCas9 platform 50 . We also cloned the two gRNAs that were predicted to have the highest efficiency (SCN9A-1 and SCN9A-2) into a single construct, since we have previously shown that higher efficacy can be achieved by using multiple gRNAs 50 . We next utilized four ZFP-KRAB constructs targeting the Na V 1.7 DNA sequence (Supplementary Table 2 ). These constructs were transfected into a mouse neuroblastoma cell line that expresses Na V 1.7 (Neuro2a) and we confirmed repression of Na V 1.7 relative to GAPDH with qPCR. Six of ten gRNAs repressed the Na V 1.7 transcript by >50% compared to the non-targeting gRNA control, with gRNA-2 being the single gRNA having the highest repression (56%) and with the dual-gRNA having repression levels of 71% (p < 0.0001), which we utilized for subsequent in vivo studies ( Supplementary Figure 1a The expression levels of Na V 1.7 was determined by qPCR, and a significant repression of Na V 1.7 was observed in mice injected with AAV9-Zinc-Finger-4-KRAB (67%; p=0.0008) compared to mice injected with AAV9-mCherry, and in mice injected with AAV9-KRAB-dCas9-dual-gRNA (50%; p=0.0033) compared to mice injected with AAV9-KRAB-dCas9-no-gRNA ( Figure 1c ). The mean paw withdrawal latencies (PWL) were calculated for both carrageenan and saline injected paws ( Supplementary Figure 2b, c) and the area under the curve (AUC) for the total mean PWL was calculated. As expected, compared to saline-injected paws, carrageenan-injected paws developed thermal hyperalgesia, measured by a decrease in PWL after application of a thermal stimulus ( Figure 1d ). We also observed a significant increase in PWL in mice injected with either AAV9-Zinc-Finger-4-KRAB or AAV9-KRAB-dCas9-dual-gRNA, indicating that the repression of Na V 1.7 in mouse DRG leads to lower thermal hyperalgesia in an inflammatory pain state. The thermal latency of the control (un-inflamed paw) was not significantly different across AAV treatment groups, indicating that the knock down of the 7 Na V 1.7 had minimal effect upon normal thermal sensitivity. As an index of edema/inflammation, we measured the ipsilateral and contralateral paws with a caliper before and 4 hours after carrageenan injection, which is the time point with the highest thermal hyperalgesia. We observed significant edema formation in both experimental and control groups, indicating that Na V 1.7 repression has no effect on inflammation Figure 2d) .
(Supplementary
Benchmarking in vivo ZFP-KRAB treatment efficacy with established small molecule drug gabapentin in a carrageenan model of inflammatory pain
To validate the efficacy of ZFP-KRAB in ameliorating thermal hyperalgesia in a carrageenan model of inflammatory pain, we next conducted a separate experiment and tested the small molecule drug gabapentin as a positive control. Mice were i.t. injected with 1E+12 vg/mouse of AAV9-mCherry (n=5), AAV9-Zinc-Finger-4-KRAB (n=6), or saline (n=5). After 21 days, thermal nociception was measured in all mice as previously described. One hour before carrageenan administration, the mice that received intrathecal saline were injected as a positive comparator with intraperitoneal (i.p.) gabapentin (100 mg/kg). This agent is known to reduce carrageenan-induced thermal hyperalgesia in rodents through binding to spinal alpha2 delta subunit of the voltage gated calcium channel 74, 75 . Twenty-four hours after carrageenan administration, mice were euthanized and DRG (L4-L6) were extracted. The expression levels of Na V 1.7
were determined by qPCR, and a significant repression of Na V 1.7 was observed in AAV9-Zinc-Finger-4-KRAB (***p=0.0007) and in the gabapentin groups (*p=0.0121) Figure 3a) . We measured the ipsilateral and contralateral paws with a caliper before and 4 hours after carrageenan injection, and confirmed significant edema formation in the injected paw of all groups as compared to the non-injected paw in all groups (Supplementary Figure 3b) . The mean PWL was calculated for both carrageenan and saline injected paws (Figure 2b, c) . We then compared paw withdrawal latencies of carrageenan injected paws for AAV9-Zinc-Finger-4-KRAB and gabapentin groups at each time point to the AAV9-mCherry carrageenan injected control using a two-way ANOVA calculation to determine whether there was any significant reduction in thermal hyperalgesia ( Supplementary Figure 3c) . When comparing carrageenan-injected hind paws, we observed that only AAV9-Zinc-Finger-4-KRAB had significantly higher PWL at all the time points following carrageenan injection when compared to the AAV9-mCherry control. We also observed significance in PWL for the gabapentin positive control group at the 30 minute, 1 hour, and four hour time points, but not the 24 hour time point. This result reflects the half-life of gabapentin (3-5 hours). We then calculated the area under the curve (AUC) for thermal hyperalgesia. We observed a significant increase in PWL in the carrageenan-injected gabapentin group (p=0.0208) (Figure 2b) , and in the Zinc-Finger-4-KRAB group (115% improvement, p=0.0021) ( Figure 2c ) compared to the carrageenan-injected AAV9-mCherry control. In addition, the AAV9-Zinc-Finger-4-KRAB group had 31% higher PWL than the gabapentin positive control group. Of note, the thermal escape latency of the contralateral non-inflamed paw showed no significant difference among groups.
(Supplementary
In vivo repression of Na V 1.7 leads to amelioration of pain in a poly neuropathic pain model
After having established in vivo efficacy in an inflammatory pain model, we went on to validate our epigenome repression strategy for neuropathic pain using the polyneuropathy model by the chemotherapeutic paclitaxel. To establish this model, mice were first injected with 1E+12 vg/mouse of AAV9-mCherry (n=8), AAV9-Zinc-Finger-4- 
In vivo repression of Na V 1.7 leads to amelioration of pain in a model of spinal evoked pain.
We next tested whether in situ repression of Na V 1.7 via KRAB-dCas9 could ameliorate neuropathic pain induced by BzATP. This molecule activates P2X receptors located on central terminals leading to a centrally mediated hyperalgesic state. We first injected mice with 1E+12 vg/mouse of AAV9-mCherry (n=6), AAV9-KRAB-dCas9-no-gRNA (n=5), and AAV9-KRAB-dCas9-dual-gRNA (n=6). After 21 days, tactile thresholds were determined with von Frey filaments, and mice were injected i.t. with BzATP (30 nmol). Tactile allodynia was then measured at 30 min, 1, 2, 3, 6, and 24 hours after BzATP administration (Figure 3d ). We observed a significant decrease in tactile allodynia at 30 min, 1 and 2 hour time points in mice injected with AAV9-KRAB-dCas9dual-gRNA, and an overall increase in tactile threshold at all time points (Figure 3e ).
Durable pain amelioration via the in situ repression of Na V 1.7 with Zinc-Finger-KRAB and KRAB-dCas9
To determine whether in situ repression of Na V 1.7 was efficacious long-term, we repeated the carrageenan inflammatory pain model and tested thermal hyperalgesia at 
DISCUSSION
In this study, we investigated the efficacy of the repression of Na V 1.7 in the dorsal root ganglia using two independent genome engineering platforms -KRAB-dCas9 and Zinc-Finger-KRAB proteins-to treat acute and persistent nociceptive processing generated in murine models of peripheral inflammation and poly neuropathy. We believe the promising results suggest the utility of the approach for developing a therapeutic reagent.
Development of targeted constructs
The work employed multiple guide-RNAs (gRNAs) clones which were rationally designed using an in silico tool 73 that predicts effective gRNAs based on chromatin position and sequence features into the split-dCas9 platform 50 . Similarly, we devised multiple ZFP-KRAB Na V 1.7 DNA targeting constructs. These constructs were transfected into a murine neuroblastoma cell line that expresses Na V 1.7 (Neuro2a) and repression of Na V 1.7 was confirmed. Constructs showing the highest level of repression were chosen for subsequent in vivo studies.
Although other technologies, such as RNAi have been utilized to target Na V 1.7, a recent study has shown that the off-target effects of RNAi, as compared to CRISPRi, are far stronger and more pervasive than generally appreciated 76, 77 . In addition, as an exogenous system, CRISPR and ZFPs (unlike RNAi) do not compete with endogenous machinery such as microRNA or RISC complex function. Thus, RNAi can have an impact in the regular homeostatic mechanisms of RNA synthesis and degradation. In addition, CRISPR and ZFP methods target genomic DNA instead of RNA, which means that to achieve an effect, RNAi methods require a higher dosage with poorer pharmacokinetics prospects, as there is usually a high RNA turnover 46 .
In vivo spinal Na V 1.7 knock down
In these studies, we found that mice injected with either epigenetic platform had significantly reduced DRG expression of Na V 1.7. Other studies have shown that partial repression of Na V 1.7 [78] [79] [80] [81] [82] [83] is sufficient to ameliorate pain. This knock down serves to produce a significant reversal of the hyperalgesia induced by hind paw inflammation.
Using antisense oligonucleotides, mechanical pain could be ameliorated with 30 to 80% Na V 1.7 repression levels 81 . Using microRNA 30b, around 50% repression of Na V 1.7 relieved neuropathic pain 82 , while more recently microRNA182 ameliorated pain preventing Na V 1.7 overexpression in spared nerve injury rats 79 . Similarly, shRNA mediated knockdown of Na V 1.7 prevented its overexpression in burn injury relieving pain 78 . Other studies did not quantify the Na V 1.7 repression levels needed to reduce pain 80 . Additionally, shRNA lentiviral vectors can reduce bone cancer pain by repressing Na V 1.7 40 to 60% 83 . Further studies are needed to determine what the minimum dosage to have an effect is.
The role of Na V 1.7 has been implicated in a variety of preclinical models, including those associated with robust inflammation as in the rodent carrageenan and CFA model. We examined the effect of knocking down Na V 1.7 in a paclitaxel-induced poly neuropathy. Previous work has shown that this treatment will induce Na V 1.7 64, 87 .
Both epigenetic repressors ameliorate tactile allodynia to the same extent as the internal comparator gabapentin. Finally, we further addressed the role of Na V 1.7 knock down in hyperpathia induced by i.t. injection of BzATP. This was significantly attenuated in mice previously treated with KRAB-dCas9. Spinal purine receptors have been shown to play a pivotal role in the nociceptive processing initiated by a variety of stimulus conditions including inflammatory/incisional pain and a variety of neuropathies 72, [88] [89] [90] . The present observations suggest that the repression of afferent Na V 1.7 expression in the nociceptor leads to a suppression of enhanced tactile sensitivity induced centrally. The mechanism underlying these results may reflect upon the observation that down regulation of Na V 1.7 in the afferent may serve to minimize the activation of microglia and astrocytes 83 . These results suggest that, at least partially, pain signal transduction through Na V 1.7 is downstream of ATP signaling.
We chose gabapentin as a positive control due to evidence that it decreases carrageenan-induced thermal hyperalgesia in rodents and because it is known to repress Na V 1.7. Our results are consistent with previous studies that showed a inhibitory effect of gabapentin on Na V 1.7 expression levels, ultimately leading to a reduction of neuronal excitability 91 . In addition, although it has been previously reported that gabapentin can lower inflammation on rat paw edema induced by carrageenan 92 , we did not find any reduction in inflammation in the gabapentin group This could be due to a difference in animal model, gabapentin dosage, or the concentration of carrageenan injected. Because only one dosage of gabapentin was utilized for these experiments, an additional group of mice receiving a different gabapentin dosage or with a second dosage can be utilized as a secondary positive control.
Of note, these drug effects examined in the polyneuropathy and carrageenan model appeared to persist unchanged for at least 6-7 weeks. Long term expression has been similarly noted in other gene therapy studies 57, [93] [94] [95] . Importantly, these effects were unaccompanied by any detectable adverse motor effects or changes in bladder function.
Spinal route for therapeutic delivery
The presented research shows efficacy of spinal reduction in Na V 1.7 in three models of hyperpathia using two complementary epigenetic tools. These studies clearly established significant target engagement and clear therapeutic efficacy with no evident adverse events after intrathecal knock down of Na V 1.7 with two independent platforms. The intrathecal route of delivery represents an appropriate choice for this therapeutic approach. The role played by Na V 1.7 is in the nociceptive afferents, and their cell bodies are in the respective segmental DRG neurons. Accordingly, the DRG represents the target for this transfection motif. The intrathecal delivery route efficiently place AAVs to the DRG neurons which minimizes the possibility of off target biodistribution and reduces the viral load required to get transduction. Importantly, the relative absence of B and T cells 96, 97 in the cerebrospinal fluid, reduces the potential immune response. In this regard, as ZFPs are engineered on human protein chasses, they intrinsically constitute a targeting approach with even lower potential immunogenicity. Indeed, a study in non-human primates (NHP) found that intrathecal delivery of a non-self protein (AAV9-GFP) produced immune responses which were not seen with the delivery of a self-protein 98 .
Future directions
These results displaying target engagement and efficacy provide strong support for the development of these platforms for pain control. Several issues are pertinent:
One, further studies are needed to determine what is the minimum effective AAV dosage to produce knock down and therapeutic effects. Two, this work showed reduction in Na V 1,7 at 21, 42, and 49 days after AAV injections and corresponding changes in pain behavior. However, still longer-term studies need to be performed to evaluate the actual duration of treatment and whether any compensatory mechanisms take place due to 13 Na V 1.7 repression. Three, further studies must be performed to explore the properties of repeat-dosing. Four, we validated our approach in three mouse pain models. However, other models of inflammatory pain should be tested to further validate our results. Carrageenan produces a model of persistent pain and hyperalgesia that best represents an acute phase from 1-24 hours and that converts to chronic inflammation by two weeks 61 . Therefore, the performed experiments can be repeated two-weeks after administering carrageenan to determine efficacy in a chronic inflammatory pain state.
The Complete Freund's adjuvant (CFA) model, collagen type II antibodies (CAIA) or K/BxN transgenic mice mimic the pathology of rheumatoid arthritis such as: widespread inflammation with the greatest effect distally, cartilage degradation, and elevated inflammatory cytokines in the joint fluid, and are thus additional important models to explore 59 . Focus on visceral pain will also be an important direction moving forward.
Finally, five, other species including rats must be explored to further validate this approach.
Therapeutic utility of intrathecal CRISPR/ZFP.
As a potential clinical treatment, KRAB-dCas9 and ZFP-KRAB show promise for treating chronic inflammatory and neuropathic pain. These systems allow for potentially reversible gene therapy, which is advantageous in the framework of chronic pain, as permanent pain insensitivity is not desired. Additionally, the weeks-long duration presents a significant advantage compared to existing drugs which must be taken daily or hourly, and which may have undesirable addictive effects. Taken together, the results of these studies show a promising new avenue for treatment of chronic pain, a significant and increasingly urgent issue in our society. For instance, cancer treatment related side effects, and in particular chemotherapy induced polyneuropathy is one of the most common adverse events which could potentially be targeted using this system 101, 102 . In this instance, a therapeutic approach that endures for months is preferable to one that is irreversible. Furthermore, the use of multiple neuraxial interventions over time is a common motif for clinical interventions as with epidural steroids where repeat epidural delivery may occur over the year at several month intervals 103 . Taken together, we anticipate this genomically scarless and non-addictive pain amelioration approach enabling long-lasting analgesia via targeted in vivo epigenetic repression of Nav1.7, will have significant therapeutic potential, such as for preemptive administration in anticipation of a pain stimulus (pre-operatively), or during an established chronic pain state.
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MATERIALS AND METHODS
Vector Design and Construction
Cas9 and Zinc-Finger AAV vectors were constructed by sequential assembly of corresponding gene blocks (Integrated DNA Technologies) into a custom synthesized rAAV2 vector backbone. gRNA sequences were inserted into dNCas9 plasmids by cloning oligonucleotides (IDT) encoding spacers into AgeI cloning sites via Gibson assembly. gRNAs were designed utilizing an in silico tool to predict gRNAs 73 .
Mammalian Cell Culture
Neuro2a cells were grown in EMEM supplemented with 10% fetal bovine serum (FBS) and 1% Antibiotic-Antimycotic (Thermo Fisher Scientific) in an incubator at 37°C and 5% CO 2 atmosphere.
Lipid-Mediated Cell Transfections
One day prior to transfection, Neuro2a cells were seeded in a 24-well plate at a cell 
Production of AAVs
Virus was prepared by the Gene Transfer, Targeting and Therapeutics (GT3) core at the Salk Institute of Biological Studies (La Jolla, CA) or in-house utilizing the GT3 core protocol. Briefly, AAV2/1, AAV2/5, and AAV2/9 virus particles were produced using HEK293T cells via the triple transfection method and purified via an iodixanol gradient.
Confluency at transfection was between 80% and 90%. Media was replaced with pre- 
Intrathecal AAV Injections
Anesthesia was induced with 2.5% isoflurane delivered in equal parts O 2 and room air in a closed chamber until a loss of the righting reflex was observed. The lower back of mice was shaven and swabbed with 70% ethanol. Mice were then intrathecally (i.t.) injected using a Hamilton syringe and 30G needle as previously described 104 Cold allodynia: Cold allodynia was measured by applying drops of acetone to the plantar surface of the hind paw as previously described 109, 110 . Membranes were then incubated overnight at 4°C with primary antibodies: anti-Na V 1.7 diluted 1:1000 (Abcam; ab85015) and anti-GAPDH (Cell Signaling, 2118) diluted 1:4000.
Membranes were then washed three times with TBS-T and incubated for 1 h at room temperature with anti-rabbit horseradish-peroxidase-conjugated secondary antibody (Cell Signaling, 7074) diluted 1:20000. After being washed with TBST, blots were visualized with SuperSignal West Femto Chemiluminescent Substrate (Thermo Fisher) and visualized on an X-ray film.
RNAscope ISH Assays
The mCherry, and Na V 1.7 probes were designed by Advanced Cell Diagnostics (Hayward, CA). The mCherry probe (ACD Cat# 404491) was designed to detect 1480-2138 bp (KF450807.1, C1 channel), and the Na V 1.7 (ACD Cat#313341), was designed to detect 3404-4576 bp of the Mus musculus Na V 1.7 mRNA sequence (NM_018852.2, C3 channel). Before sectioning, DRG were placed into 4% PFA for 2 hours at room temperature, followed by incubation in 30% sucrose overnight at 4°C. Tissues were sectioned (12 µm thick) and mounted on positively charged microscopic glass slides (Fisher Scientific). All hybridization and amplification steps were performed following the ACD RNAscope V2 fixed tissue protocol. Stained slides were coverslipped with fluorescent mounting medium (ProLong Gold Anti-fade Reagent P36930; Life Technologies) and scanned into digital images with a Zeiss 880 Airyscan Confocal at 20x magnification. Data was processed using ZEN software (manufacturer-provided software).
Statistical analysis
Results are expressed as mean +/-standard error (SE). Statistical analysis was performed using GraphPad Prism (version 8.0, GraphPad Software, San Diego, CA, USA). Results were analyzed using Student's t-test (for differences between two groups), one-way ANOVA (for multiple groups), or two-way ANOVA with the Bonferroni post hoc test (for multiple groups time-course experiments). Differences between groups with p < 0.05 were considered statistically significant.
